GlaxoSmithKline Egypt S.A.E. specializes in the development, manufacture and marketing of medicines. Their products are for the treatment of diabetes, asthma, cancer, hepatic viruses, infections, allergies and gastro-intestinal and cardiovascular diseases.

Employees

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change	Volume
20/08/26	EGP 425.03	-10.14%	189,300
19/08/26	EGP 473.00	-4.44%	237,187
18/08/26	EGP 495.00	-2.37%	207,869
17/08/26	EGP 507.00	+4.43%	748,452
16/08/26	EGP 485.50	-6.82%	206,211

End-of-day quote Egyptian Exchange

More quotes

End-of-day quote Egyptian Exchange 20/08/2026			5-day change	1st Jan Change
425.03 ^EGP	-10.14%		-18.42%	+567.76%

08-13	GlaxoSmithKline S.A.E Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
05-17	GlaxoSmithKline Q1 consol net profit EGP 4.7 million	RE

Market Cap	35.5B 698M 597M 557M 511M 961M 66.76B 980M 6.61B 2.58B 33.46B 2.62B 2.56B 111B	P/E 2024	17.3x	P/E 2025	24.9x
Enterprise Value	35.1B 690M 591M 551M 506M 950M 66.01B 969M 6.54B 2.55B 33.08B 2.59B 2.53B 110B	EV / Sales 2024	1.02x	EV / Sales 2025	1.32x
Free-Float	2.91%	Yield 2024	2.78%	Yield 2025	1.18%

08-13	GlaxoSmithKline S.A.E Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
05-17	GlaxoSmithKline Q1 consol net profit EGP 4.7 million	RE
03-12	GlaxoSmithKline S.A.E Reports Earnings Results for the Full Year Ended December 31, 2025	CI
03-12	GlaxoSmithKline FY dividend EGP 0.75 per share	RE
03-12	GlaxoSmithKline FY consol profit EGP 213.2 million	RE
12-30	GlaxoSmithKline S.A.E announces Annual dividend, payable on January 14, 2026	CI
11-19	GlaxoSmithKline S.A.E Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
11-13	GlaxoSmithKline Q3 consol loss EGP 34.8 million	RE
12/08/25	GlaxoSmithKline S.A.E Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
12/08/25	GlaxoSmithKline posts Q2 consol profit EGP 5.9 mln	RE
14/05/25	GlaxoSmithKline S.A.E Reports Earnings Results for the First Quarter Ended March 31, 2025	CI
14/05/25	Glaxosmithkline Reports Q1 Net Profit EGP 43.5 Million	RE
09/03/25	GlaxoSmithKline S.A.E Reports Earnings Results for the Full Year Ended December 31, 2024	CI

10/03/22	GlaxoSmithKline E : Glaxo Smith Kline (BIOC.CA) - Listing Committee Decision	PU
20/12/21	GSK hires former Tesco boss Sir Dave Lewis to head up £40bn spin-off	AQ

GlaxoSmithKline S.A.E Stock

Stocks

BIOC

EGS38171C012

Pharmaceuticals

Valuation: GlaxoSmithKline S.A.E

Chart: GlaxoSmithKline S.A.E

Latest news : GlaxoSmithKline S.A.E

Press Releases: GlaxoSmithKline S.A.E

Quotes and Performance

Course Extremes

Managers and Directors: GlaxoSmithKline S.A.E

Other Pharmaceuticals

Financials

Company Profile

Quotes

1 day	-10.14%
1 week	-18.42%
Current month	+77.27%
1 month	+260.19%
3 months	+502.03%
6 months	+563.69%
Current year	+567.76%

1 week	425.01	555
1 month	113.25	609
Current year	55.1	609
1 year	52.1	609
3 years	24.7	609
5 years	16.66	609
10 years	0	609

Director	Title	Age	Since
Sherine El-Ansari BRD	Director/Board Member	-	-
Ashraf Mohammed Ibrahim Mansour CHM	Chairman	-	-
Munir Ghabour Hanna BRD	Director/Board Member	-	-

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
GLAXOSMITHKLINE S.A.E	-10.14%	-18.42%	+733.39%	+1,254.03%	698M
ELI LILLY AND COMPANY	+1.61%	+7.45%	+78.66%	+130.55%	1,109B
JOHNSON & JOHNSON	+1.44%	+4.26%	+51.70%	+62.20%	644B
ABBVIE INC.	+1.44%	+6.47%	+26.78%	+76.87%	463B
ROCHE HOLDING AG	+1.02%	+5.77%	+43.09%	+47.70%	371B
NOVARTIS AG	+0.85%	+4.07%	+23.88%	+41.58%	301B
ASTRAZENECA PLC	+1.26%	+6.81%	+1.59%	+14.67%	256B
AMGEN INC.	+1.83%	+5.89%	+48.65%	+68.65%	234B
NOVO NORDISK A/S	+1.59%	+2.09%	-15.52%	-52.29%	205B
GILEAD SCIENCES, INC.	+2.75%	+6.70%	+27.11%	+94.40%	178B
Average	+0.35%	+1.46%	+101.93%	+173.84%	376.18B
Weighted average by Cap.	+1.46%	+3.25%	+45.22%	+73.76%

	2024	2025
Net sales	2.99B 58.78M 50.33M 46.96M 43.09M 80.97M 5.62B 82.56M 557M 217M 2.82B 221M 216M 9.33B	3.73B 73.32M 62.78M 58.57M 53.75M 101M 7.02B 103M 695M 271M 3.52B 275M 269M 11.64B
Net income	174M 3.42M 2.93M 2.73M 2.51M 4.71M 327M 4.8M 32.41M 12.63M 164M 12.84M 12.56M 543M	213M 4.19M 3.59M 3.35M 3.07M 5.77M 401M 5.89M 39.72M 15.48M 201M 15.74M 15.39M 665M
Net Debt	44.01M 865K 741K 691K 634K 1.19M 82.77M 1.21M 8.2M 3.2M 41.48M 3.25M 3.18M 137M	-398M -7.82M -6.7M -6.25M -5.73M -10.77M -748M -10.99M -74.12M -28.89M -375M -29.37M -28.73M -1.24B